Literature DB >> 6253277

Characterization of a specific receptor for somatomedin C (SM-C) on cultured human lymphocytes: evidence that SM-C modulates homologous receptor concentration.

R G Rosenfeld, R L Hintz.   

Abstract

A membrane receptor for somatomedin C (SM-C) on cultured IM-9 cells has recently been reported. The current studies were undertaken to further characterize this intact cellular receptor in terms of both kinetics and specificity and to investigate the ability of SM-C to induce homologous receptor loss. The binding of [125I]iodo-SM-C was rapid, achieving a steady state within 90 min and was greater than 95% reversible. Specific binding at 15C averaged 25-30% for 20 X 10(6) cells/ml. Competition for binding was observed at SM concentrations as low as 2 mU/ml, with half-maximal displacement of [125I]iodo-SM-C at SM concentrations of 33 mU/ml (3.33 X 10(-9) M). Insulin-like growth factor I (IGF-I) and a purified SM-C preparation were approximately equipotent in their ability to displace [125I]iodo-SM-C from the IM-9 receptor. The relative potencies of other growth-related peptides, in comparison with SM-C/IGF-I, were IGF-II (1:10), multiplication stimulating activity (1:10), insulin (1:100), and hGH (nonreactive). Preexposure of IM-9 cells to SM-C at 37 C resulted in a time- and concentration-dependent reduction in [125I]iodo-SM-C. A 10-15% decrease in binding was observed after preincubation with SM in concentrations of 7 mU/ml. Preincubation with 100 mU/ml SM resulted in 50% reduction in binding, but no further decreases were observed after preincubation with higher concentrations of SM (up to 1 U/ml). Scatchard analysis indicated that the reduction in binding was due to a loss of available specific receptors on the cell membrane. These data indicate that the IM-9 cell possesses a specific SM receptor and that SM-C and IGF-I compete equally for occupancy. Furthermore, the data provide a direct demonstration in cell culture that SM-C, like insulin and growth hormone, can modulate homologous receptor concentrations and potentially alter target-cell sensitivity.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6253277     DOI: 10.1210/endo-107-6-1841

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  14 in total

1.  High affinity binding sites for proinsulin in human IM-9 lymphoblasts.

Authors:  P M Jehle; M P Lutz; R D Fussgaenger
Journal:  Diabetologia       Date:  1996-04       Impact factor: 10.122

2.  Novel roles of Akt and mTOR in suppressing TGF-beta/ALK5-mediated Smad3 activation.

Authors:  Kyung Song; Hui Wang; Tracy L Krebs; David Danielpour
Journal:  EMBO J       Date:  2005-12-15       Impact factor: 11.598

3.  Expression and characterization of an antibody binding specificity joined to insulin-like growth factor 1: potential applications for cellular targeting.

Authors:  S U Shin; S L Morrison
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

4.  Insulin suppresses growth hormone secretion by rat pituitary cells.

Authors:  S Melmed
Journal:  J Clin Invest       Date:  1984-05       Impact factor: 14.808

5.  Cumulative activation of akt and consequent inhibition of glycogen synthase kinase-3 by brain-derived neurotrophic factor and insulin-like growth factor-1 in cultured hippocampal neurons.

Authors:  Nadine N Johnson-Farley; Tatyana Travkina; Daniel S Cowen
Journal:  J Pharmacol Exp Ther       Date:  2005-11-11       Impact factor: 4.030

6.  Structural and functional characterization of the human T lymphocyte receptor for insulin-like growth factor I in vitro.

Authors:  V F Tapson; M Boni-Schnetzler; P F Pilch; D M Center; J S Berman
Journal:  J Clin Invest       Date:  1988-09       Impact factor: 14.808

7.  Regulation of insulin-like growth factor (IGF) I receptor expression during muscle cell differentiation. Potential autocrine role of IGF-II.

Authors:  S M Rosenthal; A Brunetti; E J Brown; P W Mamula; I D Goldfine
Journal:  J Clin Invest       Date:  1991-04       Impact factor: 14.808

8.  Enhancing engineered vascular networks in vitro and in vivo: The effects of IGF1 on vascular development and durability.

Authors:  Claudia C Friedrich; Yunfeng Lin; Alexander Krannich; Yinan Wu; Joseph P Vacanti; Craig M Neville
Journal:  Cell Prolif       Date:  2017-11-07       Impact factor: 6.831

9.  Interaction of FGF-2 with IGF-1 and BDNF in stimulating Akt, ERK, and neuronal survival in hippocampal cultures.

Authors:  Nadine N Johnson-Farley; Khushboo Patel; Deborah Kim; Daniel S Cowen
Journal:  Brain Res       Date:  2007-04-19       Impact factor: 3.252

10.  Insulin-like growth factor binding to the atypical insulin receptors of a human lymphoid-derived cell line (IM-9).

Authors:  H A Jonas; A J Cox
Journal:  Biochem J       Date:  1990-03-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.